Details:
SNAs are nanoscale constructs consisting of synthetic nucleic acid sequences densely radiating from a spherical core. SNA-based Therapeutic gives rise to distinct chemical and biological properties and may provide advantages over other nucleic acid therapeutics.
Lead Product(s): SNA-based Therapeutic
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Ipsen
Deal Size: $1,020.0 million Upfront Cash: $20.0 million
Deal Type: Termination December 14, 2022
Details:
Under the agreement, Ipsen will receive exclusive options to license SNA-based therapeutics arising from two collaboration programs for Huntington’s disease and Angelman syndrome.
Lead Product(s): SNA-based Therapeutics
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Ipsen
Deal Size: $1,020.0 million Upfront Cash: $20.0 million
Deal Type: Collaboration August 02, 2021